Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption

Introduction: Granulocyte colony-stimulating factor (G-CSF) is the first line treatment for mobilization, most commonly using a regimen of daily filgrastim. The use of biosimilars can provide substantial cost savings to the health care system while delivering comparable efficacy outcomes. In 2016, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Aggarwal, Vibhuti, Sabry, Waleed, Elemary, Mohamed, Bosch, Mark, Danyluk, Pat, Mondal, Prosanta, Stakiw, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161742/
https://www.ncbi.nlm.nih.gov/pubmed/33922026
http://dx.doi.org/10.3390/curroncol28030148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161742/
https://www.ncbi.nlm.nih.gov/pubmed/33922026
http://dx.doi.org/10.3390/curroncol28030148

Ejemplares similares